# REGENXBIO Inc.: overview RGNX · Nasdaq · CIK 1590877 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/rgnx.md) · [Financials](/companies/rgnx/financials.md) · [Filings](/companies/rgnx/filings.md) · [Insiders](/companies/rgnx/insiders.md) Latest reported revenue: [$108.0m](/filings/0001193125-26-336725.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-336725). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [24.2](/filings/0001193125-25-268095.md) | [21.2 d](/filings/0001193125-26-094013.md) | [89.0](/filings/0001193125-26-222804.md) | [21.4](/filings/0001193125-26-336725.md) | [29.7](/filings/0001193125-25-268095.md) | [30.3 d](/filings/0001193125-26-094013.md) | [6.4](/filings/0001193125-26-222804.md) | [108](/filings/0001193125-26-336725.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(256.6%)](/filings/0001193125-25-268095.md) | [(242.1%) d](/filings/0001193125-26-094013.md) | [13.6%](/filings/0001193125-26-222804.md) | [(296.3%)](/filings/0001193125-26-336725.md) | [(176.3%)](/filings/0001193125-25-268095.md) | [(190.0%) d](/filings/0001193125-26-094013.md) | [(1304.0%)](/filings/0001193125-26-222804.md) | [27.1%](/filings/0001193125-26-336725.md) | | Net margin | % | [(246.3%)](/filings/0001193125-25-268095.md) | [(241.3%) d](/filings/0001193125-26-094013.md) | [6.8%](/filings/0001193125-26-222804.md) | [(331.8%)](/filings/0001193125-26-336725.md) | [(208.3%)](/filings/0001193125-25-268095.md) | [(221.3%) d](/filings/0001193125-26-094013.md) | [(1408.6%)](/filings/0001193125-26-222804.md) | [21.0%](/filings/0001193125-26-336725.md) | | Diluted EPS | $ per share | [(1.17)](/filings/0001193125-25-268095.md) | not reported | [0.12](/filings/0001193125-26-222804.md) | [(1.38)](/filings/0001193125-26-336725.md) | [(1.20)](/filings/0001193125-25-268095.md) | not reported | [(1.72)](/filings/0001193125-26-222804.md) | [0.43](/filings/0001193125-26-336725.md) | | Free cash flow | $m | [(40.9) d](/filings/0001193125-25-268095.md) | [(32.7) d](/filings/0001193125-26-094013.md) | [32.6](/filings/0001193125-26-222804.md) | [(49.7) d](/filings/0001193125-26-336725.md) | [(56.5) d](/filings/0001193125-25-268095.md) | [(52.8) d](/filings/0001193125-26-094013.md) | [(77.4)](/filings/0001193125-26-222804.md) | [(63.0) d](/filings/0001193125-26-336725.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [470](/filings/0000950170-24-021161.md) | [113](/filings/0000950170-25-038770.md) | [90.2](/filings/0000950170-25-038770.md) | [83.3](/filings/0001193125-26-094013.md) | [170](/filings/0001193125-26-094013.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [34.0%](/filings/0000950170-24-021161.md) | [(233.2%)](/filings/0000950170-25-038770.md) | [(297.1%)](/filings/0000950170-25-038770.md) | [(280.0%)](/filings/0001193125-26-094013.md) | [(94.6%)](/filings/0001193125-26-094013.md) | | Net margin | % | [27.2%](/filings/0000950170-24-021161.md) | [(248.7%)](/filings/0000950170-25-038770.md) | [(292.0%)](/filings/0000950170-25-038770.md) | [(272.5%)](/filings/0001193125-26-094013.md) | [(113.8%)](/filings/0001193125-26-094013.md) | | Diluted EPS | $ per share | [2.91](/filings/0000950170-24-021161.md) | [(6.50)](/filings/0000950170-25-038770.md) | [(6.02)](/filings/0000950170-25-038770.md) | [(4.59)](/filings/0001193125-26-094013.md) | [(3.76)](/filings/0001193125-26-094013.md) | | Free cash flow | $m | [135](/filings/0000950170-24-021161.md) | [(238)](/filings/0000950170-25-038770.md) | [(228)](/filings/0000950170-25-038770.md) | [(176)](/filings/0001193125-26-094013.md) | [(126)](/filings/0001193125-26-094013.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rgnx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $76.6m | 6,397,440 | | Added +614,632 | | [Redmile Group, LLC](/funds/1425738.md) | 2026-06-30 | $52.3m | 4,368,804 | | Unchanged | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $35.6m | 2,971,173 | | Added +239,688 | | [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $26.2m | 2,214,169 | | Reduced −1,269,631 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $25.2m | 2,107,557 | | Added +100,411 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $23.4m | 1,953,237 | | Reduced −112,920 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $17.0m | 1,421,453 | | Reduced −418,010 | | [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $16.5m | 1,378,358 | | Added +326,646 | | [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $16.2m | 1,355,554 | | Added +336,653 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $15.4m | 1,284,950 | | New +1,284,950 | ## Recent filings [All 779 filings](/companies/rgnx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-16 | 11:00 ET | [8-K](/filings/0001193125-26-423376.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-423376 | | 2026-09-23 | 20:05 ET | [8-K](/filings/0001193125-26-399377.md) | 1.01 Entry into a material agreement | 0001193125-26-399377 | | 2026-08-25 | 20:57 ET | [8-K](/filings/0001193125-26-365287.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-365287 | | 2026-08-24 | 21:20 ET | [8-K](/filings/0001193125-26-363786.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-363786 | | 2026-08-06 | 11:15 ET | [10-Q](/filings/0001193125-26-336725.md) | Quarterly report, period 2026-06-30 | 0001193125-26-336725 | | 2026-08-06 | 11:10 ET | [8-K](/filings/0001193125-26-336716.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-336716 | | 2026-07-20 | 11:34 ET | [8-K](/filings/0001193125-26-308342.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-308342 | | 2026-06-29 | 11:15 ET | [8-K](/filings/0001193125-26-286825.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-286825 | | 2026-06-03 | 11:30 ET | [8-K](/filings/0001193125-26-254590.md) | 5.07 Shareholder vote results; 8.01 Other events | 0001193125-26-254590 | | 2026-05-14 | 11:30 ET | [10-Q](/filings/0001193125-26-222804.md) | Quarterly report, period 2026-03-31 | 0001193125-26-222804 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-094013.md), filed Mar 5, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/f6d9a197-9b38-4cd5-8af0-403f5ef589c0) ## About the filer - CIK: 1590877 - Tickers: RGNX - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: not reported - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.